Oversubscribed spherical co-led by Cormorant Asset Administration and Fairmount Funds, supported by a robust syndicate of latest and present traders
PHILADELPHIA, Could 18, 2021 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene remedy firm creating a paradigm-shifting platform for in vivo cell-specific gene supply, in the present day introduced that it has raised $76 million in an oversubscribed Collection A financing. The spherical was co-led by Cormorant Asset Administration and Fairmount Funds, and joined by Bain Capital Life Sciences, Pfizer Ventures, RA Capital Administration, Longwood Fund, Logos Capital, Osage College Companions and Quan Capital. All present traders participated, together with lead founding investor Tellus BioVentures, the College of Pennsylvania and Penn Medication, Agent Capital, the Mark Basis for Most cancers Analysis, Knollwood, and BrightEdge, the American Most cancers Society’s impression funding fund. Tomas Kiselak of Fairmount Funds and Ben Lund of Bain Capital Life Sciences will be part of the Interius Board of Administrators.
“We had been gratified by the distinctive curiosity throughout our elevate and are delighted by the composition of the syndicate – a testomony to the potential of the know-how and the stable scientific basis from Dr. Gill’s lab and the Middle for Mobile Immunotherapies at Penn,” mentioned Phil Johnson, MD, CEO of Interius. “I look ahead to working with this superb workforce as we advance our gene supply platform that can allow extremely particular, sturdy re-engineering of cells proper the place they dwell within the human physique.”
Co-founded by Dr. Saar Gill, physician-scientist on the College of Pennsylvania, and Bruce Peacock, a famend biotech veteran, Interius is initially targeted on treating hematologic malignancies by leveraging its novel gene supply platform to generate chimeric antigen receptor (CAR) T cells immediately in vivo. This distinctive therapeutic strategy bypasses the necessity for ex vivo cell manipulations and the doubtless poisonous pre-conditioning chemotherapy required for normal CAR T-cell remedies. Exploiting its versatile platform, Interius can be creating functions past immuno-oncology that deal with ailments not amenable to present gene remedy modalities.
“We’re very happy to have assembled a incredible workforce at Interius who’re translating breakthrough science with the assist of a world-class group of traders,” mentioned Lonnie Moulder, Board Chair and Managing Member of Tellus BioVentures. “The know-how that Interius is advancing might dramatically change the best way we take into consideration in vivo gene supply and result in transformational therapies for sufferers.”
About Interius BioTherapeutics
Interius BioTherapeutics is a preclinical stage gene remedy firm creating novel strategies for in vivo cell-specific gene supply, making a breakthrough platform with multi-product potential. The corporate was based based mostly on innovations from the laboratory of Dr. Saar Gill, a number one physician-scientist within the fields of cell and gene remedy on the Middle for Mobile Immunotherapies on the College of Pennsylvania. Interius BioTherapeutics is headquartered in Philadelphia, PA. For extra info, go to www.interiusbio.com
View authentic content material to obtain multimedia:http://www.prnewswire.com/news-releases/interius-biotherapeutics-raises-76m-series-a-financing-to-advance-breakthrough-cell-and-gene-therapy-platform-301293111.html
SOURCE Interius BioTherapeutics, Inc.